glucagon has been researched along with Fatty Liver, Nonalcoholic in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 16 (47.06) | 2.80 |
| Authors | Studies |
|---|---|
| Feigh, M; Harris, MS; Nestor, JJ; Parkes, D; Suschak, JJ | 1 |
| Elmelund, E; Galsgaard, KD; Holst, JJ; Kjeldsen, SAS; Knop, FK; Richter, MM; Suppli, MP; Wewer Albrechtsen, NJ; Winther-Sørensen, M | 1 |
| Perry, RJ | 1 |
| Ahlström, H; Bergsten, P; Forslund, A; Kullberg, J; Manell, H; Mangge, H; Maruszczak, K; Mörwald, K; Pixner, T; Radzikowski, K; Schütz, S; Weghuber, D | 1 |
| Holst, JJ; Wewer Albrechtsen, NJ; Winther-Sørensen, M | 1 |
| Andreassen, KV; Henriksen, K; Karsdal, MA; Kayed, A; Khan, S; Melander, SA | 1 |
| Kardassis, D; Thymiakou, E; Tzardi, M | 1 |
| Biondi, G; Caruso, I; Cignarelli, A; D'Oria, R; Genchi, VA; Giorgino, F; Laviola, L; Marrano, N; Natalicchio, A; Perrini, S; Sorice, GP | 1 |
| Bartlett, PJ; Brumer, RP; Corrêa-Velloso, JC; Sandiford, OA; Thomas, AP; Thomas, SJ | 1 |
| Bloom, SR; Campbell, JE; Cherrington, AD; Dean, ED; Finan, B; Gluud, LL; Holst, JJ; Knop, FK; Müller, TD; Tan, TM; Wewer Albrechtsen, NJ | 1 |
| Brill, AL; Butrico, GM; Cline, GW; Dufour, S; Ehrlich, BE; Goedeke, L; Guerra, MT; Nasiri, AR; Nathanson, MH; Nozaki, Y; Peng, L; Perry, RJ; Petersen, KF; Rabin-Court, A; Shulman, GI; Toussaint, K; Wang, Y; Zhang, D; Zhang, XM; Zhang, Y | 1 |
| Matsuda, K; Moritoh, Y; Ookawara, M; Watanabe, M | 1 |
| Fappi, A; Mittendorfer, B | 1 |
| Andersen, DB; Bisgaard, HC; Dall, M; Eriksen, PL; Galsgaard, KD; Gillum, MP; Gluud, LL; Hassing, AS; Holst, JJ; Hunt, JE; Jepsen, SL; Kjeldsen, SAS; Knop, FK; Kuhre, RE; Pedersen, J; Santos, A; Sulek, K; Torekov, SS; Trammell, SAJ; Treebak, JT; Vasilopoulou, CG; Vilstrup, H; Werge, MP; Wewer Albrechtsen, NJ; Windeløv, JA; Winther-Sørensen, M; Ørskov, C | 1 |
| Adamski, J; Gar, C; Haschka, SJ; Holst, JJ; Kern-Matschilles, S; Lechner, A; Prehn, C; Rauch, B; Sacco, V; Seissler, J; Wewer Albrechtsen, NJ | 1 |
| Chen, C; Chen, X; Chen, Y; Lin, Z; Lu, Y; Wan, H; Wang, C; Wang, N; Wang, Y; Xia, F; Zhang, W | 1 |
| Geisler, CE; Renquist, BJ | 1 |
| Junker, AE | 1 |
| Auwerx, J; Dongiovanni, P; Kim, K; Nayak, S; Ozcan, L; Pajvani, UB; Ryu, D; Ueberheide, B; Valenti, L | 1 |
| Christensen, M; Galsgaard, KD; Holst, JJ; Hædersdal, S; Junker, AE; Knop, FK; Lund, AM; Vilsbøll, T; Wewer Albrechtsen, NJ; Wibrand, F | 1 |
| Bahekar, R; Jain, M; Joharapurkar, A; Kadam, S; Kshirsagar, S; Pandey, D; Patel, D; Patel, H; Patel, M; Patel, V; Ranvir, R; Sutariya, B | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Bao, L; Gao, W; Gao, X; Wang, Q; Yao, W; Yin, J | 1 |
| Choi, D; Jung, CH; Kang, SK; Kim, BY; Kim, CH; Lee, B; Moh Moh, MA; Mok, JO | 1 |
| Huang, F; Wang, T; Xia, J; Yao, W; Zhang, L | 1 |
| Anděl, M; Červinková, Z; Fontana, J | 1 |
| Beglinger, C; Bernsmeier, C; Blaser, LS; Heim, MH; Jeker, L; Meyer-Gerspach, AC; Steinert, RE | 1 |
| Rui, L | 1 |
| Hao, L; Huang, KH; Ito, K; Lambert, JD; Ross, AC; Sae-tan, S | 1 |
| Gluud, LL; Holst, JJ; Junker, AE; Knop, FK; van Hall, G; Vilsbøll, T | 1 |
| Gluud, L; Holst, JJ; Junker, AE; Knop, FK; Vilsbøll, T | 1 |
| Agius, L | 1 |
| Holst, JJ; Knop, FK; Kuhre, RE; Pedersen, J; Wewer Albrechtsen, NJ | 1 |
| Biebermann, H; Brandt, S; Clemmensen, C; De Angelis, M; DiMarchi, R; Döring, Y; Finan, B; Fischer, K; Flamant, F; Fuchs, H; Gailus-Durner, V; Gauthier, K; Gelfanov, V; Habegger, KM; Healy, ME; Heikenwalder, M; Hofmann, SM; Hrabě de Angelis, M; Jall, S; Jastroch, M; Keuper, M; Kleinert, M; Köhrle, J; Liu, F; Liu, P; Lutter, D; Malehmir, M; Moreth, K; Müller, L; Müller, TD; Neff, F; Perez-Tilve, D; Rozman, J; Sánchez-Garrido, MA; Schramm, KW; Stemmer, K; Tschöp, MH; Tuckermann, J; Weber, A; Weber, C; Yang, B; Zhu, Z | 1 |
14 review(s) available for glucagon and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Liver-α-Cell Axis in Health and in Disease.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Hepatocytes; Humans; Insulin; Non-alcoholic Fatty Liver Disease | 2022 |
Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1.
Topics: Calcium; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Inositol 1,4,5-Trisphosphate Receptors; Lipid Metabolism; Lipids; Liver; Non-alcoholic Fatty Liver Disease | 2022 |
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease.
Topics: Amino Acids; Animals; Diabetes Mellitus, Type 2; Feedback; Glucagon; Glucose; Humans; Hyperglycemia; Lipids; Non-alcoholic Fatty Liver Disease | 2023 |
Glucagon in type 2 diabetes: Friend or foe?
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease | 2023 |
100 years of glucagon and 100 more.
Topics: Amino Acids; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hyperglycemia; Non-alcoholic Fatty Liver Disease | 2023 |
Dietary protein intake and obesity-associated cardiometabolic function.
Topics: Animals; Blood Glucose; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diet, High-Protein; Diet, High-Protein Low-Carbohydrate; Dietary Proteins; Glucagon; Humans; Insulin; Non-alcoholic Fatty Liver Disease; Obesity; Triglycerides | 2020 |
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Topics: Adipose Tissue; Animals; Diet; Endocrine System Diseases; Fatty Liver; Glucagon; Gluconeogenesis; Glucose; Homeostasis; Hormones; Humans; Hydrocortisone; Hyperinsulinism; Lipid Metabolism; Lipids; Lipogenesis; Lipolysis; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Overnutrition; Oxidation-Reduction; Signal Transduction; Virus Diseases | 2017 |
The role of incretin hormones and glucagon in patients with liver disease.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Intolerance; Humans; Incretins; Insulin; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism.
Topics: Acetylation; Animals; Energy Metabolism; Fasting; Glucagon; Glucose; Homeostasis; Humans; Lipid Metabolism; Liver; Liver Neoplasms; Non-alcoholic Fatty Liver Disease | 2019 |
[Effects of GLP-1 (glucagon-like peptide 1) on liver].
Topics: Animals; Glucagon; Glucagon-Like Peptide 1; Hepatocytes; Humans; Hypoglycemic Agents; Incretins; Insulin; Lipid Metabolism; Liver Diseases; Non-alcoholic Fatty Liver Disease; Oxidative Stress | 2013 |
Energy metabolism in the liver.
Topics: Circadian Rhythm; Cytokines; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Energy Metabolism; Fatty Acids; Glucagon; Gluconeogenesis; Glucose; Human Growth Hormone; Humans; Insulin; Lipogenesis; Liver; Non-alcoholic Fatty Liver Disease; Obesity | 2014 |
Hormonal and Metabolite Regulation of Hepatic Glucokinase.
Topics: Adaptor Proteins, Signal Transducing; Animals; Diabetes Mellitus, Type 2; Gene Expression Regulation, Enzymologic; Glucagon; Glucokinase; Homeostasis; Humans; Liver; Models, Biological; Non-alcoholic Fatty Liver Disease; Phosphofructokinase-2; Postprandial Period; Protein Transport | 2016 |
The biology of glucagon and the consequences of hyperglucagonemia.
Topics: Diabetes Mellitus; Glucagon; Glucagon-Like Peptide 1; Glucagonoma; Humans; Liver; Neoplasms; Non-alcoholic Fatty Liver Disease; Oxyntomodulin; Pancreas; Receptors, Glucagon | 2016 |
1 trial(s) available for glucagon and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Topics: Adult; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Incretins; Insulin; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2016 |
19 other study(ies) available for glucagon and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Cholesterol; Collagen; Disease Models, Animal; Galectin 3; Glucagon; Glucagon-Like Peptide 1; Inflammation; Interleukin-2; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, Antigen, T-Cell; Receptors, Glucagon; Recombinant Fusion Proteins; Transaminases; Triglycerides | 2022 |
Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
Topics: Adolescent; Child; Glucagon; Glucose; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Obesity; Triglycerides; Uric Acid | 2022 |
The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
Topics: Animals; Body Weight; Complement C4; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Lipids; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, Glucagon | 2023 |
Impaired hepatic glucose metabolism and liver-α-cell axis in mice with liver-specific ablation of the Hepatocyte Nuclear Factor 4α (Hnf4a) gene.
Topics: Animals; Glucagon; Glucose; Hepatocyte Nuclear Factor 4; Hepatocyte Nuclear Factors; Insulin; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease | 2023 |
Short-term high-fat diet feeding of mice suppresses catecholamine-stimulated Ca
Topics: Animals; Catecholamines; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Hepatocytes; Inositol 1,4,5-Trisphosphate; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Norepinephrine | 2023 |
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.
Topics: Acetyl Coenzyme A; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; Glucagon; Gluconeogenesis; Inositol 1,4,5-Trisphosphate Receptors; Lipase; Lipolysis; Liver; Mice, Knockout; Mitochondria; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction | 2020 |
The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
Topics: Administration, Oral; Animals; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Glucagon; Glucagon-Like Peptide 1; Glucose; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptors, G-Protein-Coupled; Triglycerides | 2020 |
Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
Topics: Adult; Amino Acids; Animals; Blood Glucose; Fatty Liver; Female; Glucagon; Glucagon-Secreting Cells; Glucose; Hepatocytes; Humans; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Receptors, Glucagon; Urea | 2020 |
The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.
Topics: Adiposity; Adult; Alanine; Biomarkers; Blood Chemical Analysis; Cross-Sectional Studies; Female; Glucagon; Glucagon-Secreting Cells; Humans; Insulin Resistance; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Predictive Value of Tests; Prognosis; Prospective Studies | 2021 |
Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression.
Topics: Adult; China; Diabetes Mellitus, Type 2; Glucagon; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2021 |
Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Genetic Predisposition to Disease; Glucagon; Hep G2 Cells; Humans; Lipogenesis; Liver; Liver Neoplasms; Male; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Phenotype; Phosphoprotein Phosphatases; Phosphorylation; Proteolysis; Signal Transduction | 2017 |
Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
Topics: Adult; Aged; Amino Acids; Biomarkers; Body Mass Index; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Insulin Resistance; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Up-Regulation | 2018 |
Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Topics: Animals; Exenatide; Glucagon; Glucagon-Like Peptide 1; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Peptides; Receptors, Glucagon; Venoms | 2018 |
A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Blood Glucose; Body Weight; Delayed-Action Preparations; Disease Models, Animal; Fibroblast Growth Factors; Glucagon; Insulin; Interleukin-17; Lipids; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2018 |
Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Topics: Adiposity; Adult; Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prognosis; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Ultrasonography | 2019 |
Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
Topics: Case-Control Studies; Fatty Liver; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2014 |
Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.
Topics: Animals; Cell Line, Tumor; Diet, High-Fat; Dietary Carbohydrates; Fatty Liver; Gene Expression; Glucagon; Glucose; Hep G2 Cells; Hepatocytes; Humans; Insulin; Lipid Metabolism; Lipids; Lipogenesis; Liver; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2014 |
Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
Topics: Adult; Aged; Energy Metabolism; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Lipolysis; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2016 |
Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
Topics: Animals; Atherosclerosis; Body Weight; Bone and Bones; Chemical Engineering; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Drug Synergism; Glucagon; Hyperglycemia; Liver; Metabolic Diseases; Mice; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Obesity; Triiodothyronine | 2016 |